Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļVCYT
āļāļ·āđāļāļāļĢāļīāļĐāļąāļVeracyte Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļOct 30, 2013
āļāļĩāļāļĩāđāļStapley (Marc A)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ824
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļOct 30
āļāļĩāđāļāļĒāļđāđ6000 Shoreline Court, Suite 300
āđāļĄāļ·āļāļSOUTH SAN FRANCISCO
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ94080
āđāļāļĢāļĻāļąāļāļāđ16502436300
āđāļ§āđāļāđāļāļāđhttps://www.veracyte.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļVCYT
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļOct 30, 2013
āļāļĩāļāļĩāđāļStapley (Marc A)
Mr. Marc A. Stapley
Chief Executive Officer, Director
Chief Executive Officer, Director
Ms. Rebecca Chambers
Chief Financial Officer
Ms. Annie Mcguire
Chief Human Resources Officer, General Counsel
Chief Human Resources Officer, General Counsel
Dr. Phillip G. (Phil) Febbo, M.D.
Dr. Phillip G. (Phil) Febbo, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
Mr. John Leite, Ph.D.
Global Chief Commercial Officer
Global Chief Commercial Officer
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
Dr. Eliav Barr, M.D.
Independent Director
Ms. Muna Bhanji
Independent Director
Mr. Evan Jones
Independent Director
Mr. Jens Holstein
Independent Director
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Mr. Marc A. Stapley
Chief Executive Officer, Director
Chief Executive Officer, Director
Ms. Rebecca Chambers
Chief Financial Officer
Ms. Annie Mcguire
Chief Human Resources Officer, General Counsel
Chief Human Resources Officer, General Counsel
Dr. Phillip G. (Phil) Febbo, M.D.
Dr. Phillip G. (Phil) Febbo, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
Mr. John Leite, Ph.D.
Global Chief Commercial Officer
Global Chief Commercial Officer
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
Invesco Biotechnology & Genome ETF
ARK Genomic Revolution ETF
First Trust NYSE Arca Biotechnology Index Fund
Global X Genomics & Biotechnology ETF
ROBO Global Healthcare Technology & Innovation ETF
Invesco S&P SmallCap 600 Pure Growth ETF
Invesco S&P SmallCap Health Care ETF
Franklin Genomic Advancements ETF
ROBO Global Artificial Intelligence ETF
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Invesco Biotechnology & Genome ETF
āļŠāļąāļāļŠāđāļ§āļ4.35%
ARK Genomic Revolution ETF
āļŠāļąāļāļŠāđāļ§āļ3.68%
First Trust NYSE Arca Biotechnology Index Fund
āļŠāļąāļāļŠāđāļ§āļ3.48%
Global X Genomics & Biotechnology ETF
āļŠāļąāļāļŠāđāļ§āļ3.13%
ROBO Global Healthcare Technology & Innovation ETF
āļŠāļąāļāļŠāđāļ§āļ2.19%
Invesco S&P SmallCap 600 Pure Growth ETF
āļŠāļąāļāļŠāđāļ§āļ1.97%
Invesco S&P SmallCap Health Care ETF
āļŠāļąāļāļŠāđāļ§āļ1.74%
Franklin Genomic Advancements ETF
āļŠāļąāļāļŠāđāļ§āļ1.45%
ROBO Global Artificial Intelligence ETF
āļŠāļąāļāļŠāđāļ§āļ1.43%
ARK Innovation ETF
āļŠāļąāļāļŠāđāļ§āļ1.24%
āļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
0.00
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē

āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ